市場調査レポート

商品コード

1388955

肺がん治療薬の世界市場：疾患の種類別・治療法別・薬剤クラス別・投与経路別・流通チャネル別・地域別の評価、機会と予測 (2016年～2030年)

Lung Cancer Therapeutics Market Assessment, By Disease Type, By Treatment, By Drugs Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2016-2030F

出版日: 2023年12月01日
発行: Market Xcel - Markets and Data
ページ情報: 英文 204 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 660,690円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 836,874円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,203,924円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の肺がん治療薬の市場規模は、2022年に212億米ドルと評価され、2023年から2030年の予測期間には12.9%のCAGRで成長し、2030年には560億米ドルに達すると予測されています。肺がん治療薬の進歩は、先進国と発展途上国の両方におけるこの疾患に対する意識の高まりによって高まっています。この急成長の背景には、新しい診断ツールや最先端の治療法の進化、医療インフラや治療法の改善に対する各国政府の重点的な取り組みがあります。また、多様な肺がん治療の選択肢に対する一般市民の認識が高まっていることも、市場成長を後押しする重要な要因です。

さらに、可処分所得の増加、革新的技術の研究開発の進行、最先端の放射線療法の導入、個別化医療の重視の高まり、新興国や低開発地域における経済成長などの要因が、予測期間を通じて市場の成長軌道を後押しすると予想されます。治療選択肢の進歩は、肺がん治療薬の展望を大きく変えました。この市場では、患者の転帰と生存率の改善を目的とした新規治療、併用療法、早期診断法を探る臨床試験や調査が急増しています。世界の医療産業が腫瘍学と個別化医療を優先し続ける中、肺がん治療薬市場はさらなる進歩を遂げ、生存率の改善、治療効果の向上、診断された患者の生活の質の向上を促進すると期待されています。

当レポートでは、世界の肺がん治療薬の市場について分析し、製品の概略や市場の基本構造、全体的な市場規模の動向見通し、セグメント別・地域別の詳細動向、市場の背景事情や主な影響要因、主要企業のプロファイル・市場シェアなどを調査しております。

市場規模と予測
- 金額ベース
- 数量ベース
疾患の種類別
- 非小細胞肺がん (NSCLC)
- 小細胞肺がん (SCLC)
治療法別
- 化学療法
- 放射線治療
- 免疫療法・標的療法
- その他
薬剤クラス別
- 免疫抑制剤
- モノクローナル抗体
- チロシンキナーゼ
- 上皮成長因子受容体 (EGFR)
- トポイソメラーゼ阻害剤
- その他
投与経路別
- 経口薬
- 注射薬
流通チャネル別
- 病院
- 専門クリニック
- CRO (医薬品開発業務受託機関)
- 在宅医療
- 外来手術センター
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
企業別市場シェア (%、2022年)

第6章世界の肺がん治療薬市場の将来展望：地域別 (2016年～2030年)

北米*
- 市場規模と予測
  - 金額ベース
  - 数量ベース
- 疾患の種類別
- 治療法別
- 薬剤クラス別
- 投与経路別
- 流通チャネル別
- 米国*
  - 市場規模と予測
  - 疾患の種類別
  - 治療法別
  - 薬剤クラス別
  - 投与経路別
  - 流通チャネル別
- カナダ
- メキシコ

各セグメントの情報は、対象となる全ての地域・国について提供されます。

欧州
- ドイツ
- フランス
- イタリア
- 英国
- ロシア
- オランダ
- スペイン
- トルコ
- ポーランド
南米
- ブラジル
- アルゼンチン
アジア太平洋
- インド
- 中国
- 日本
- オーストラリア
- ベトナム
- 韓国
- インドネシア
- フィリピン
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- 南アフリカ

第7章市場マッピング (2022年)

疾患の種類別
治療法別
薬剤クラス別
投与経路別
流通チャネル別
地域別

第8章マクロ環境と産業構造

需給分析
輸出入分析 (数量・金額ベース)
サプライ/バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第9章市場力学

成長促進要因
成長抑制要因 (課題、制約)

第10章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/新興技術

第11章主要企業の情勢

市場リーダー上位5社：競合マトリックス
市場リーダー上位5社：市場収益分析 (%、2022年)
企業合併・買収 (M&A)/合弁事業 (該当する場合)
SWOT分析 (市場参入企業5社の場合)
特許分析 (該当する場合)

第12章価格分析

第13章ケーススタディ

第14章主要企業の見通し

Novartis AG

企業概要
経営幹部
製品・サービス
財務状況 (報告どおり)
重点市場と地理的プレゼンス
最近の動向

AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb Company
Eli Lilly and Company
Hoffmann-La Roche
Merck &Co.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Abbvie (Allergan)
Johnson &Johnson (Janssen Pharmaceuticals)
Amgen Inc.

上記企業は市場シェア順ではなく、調査作業中に入手した情報に従って変更される可能性があります。

第15章戦略提言

第16章 Market Xcelについて、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 2. Global Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 3. Global Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 4. Global Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 5. Global Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 6. Global Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 7. Global Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 8. Global Lung Cancer Therapeutics Market Share, By Region, In USD Billion, 2016-2030F
Figure 9. North America Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 10. North America Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 11. North America Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 12. North America Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 13. North America Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 14. North America Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 15. North America Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 16. North America Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
Figure 17. United States Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 18. United States Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 19. United States Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 20. United States Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 21. United States Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 22. United States Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 23. United States Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 24. Canada Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 25. Canada Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 26. Canada Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 27. Canada Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 28. Canada Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 29. Canada Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 30. Canada Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 31. Mexico Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 32. Mexico Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 33. Mexico Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 34. Mexico Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 35. Mexico Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 36. Mexico Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 37. Mexico Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 38. Europe Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 39. Europe Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 40. Europe Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 41. Europe Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 42. Europe Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 43. Europe Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 44. Europe Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 45. Europe Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
Figure 46. Germany Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 47. Germany Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 48. Germany Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 49. Germany Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 50. Germany Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 51. Germany Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 52. Germany Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 53. France Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 54. France Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 55. France Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 56. France Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 57. France Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 58. France Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 59. France Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 60. Italy Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 61. Italy Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 62. Italy Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 63. Italy Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 64. Italy Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 65. Italy Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 66. Italy Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 67. United Kingdom Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 68. United Kingdom Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 69. United Kingdom Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 70. United Kingdom Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 71. United Kingdom Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 72. United Kingdom Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 73. United Kingdom Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 74. Russia Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 75. Russia Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 76. Russia Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 77. Russia Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 78. Russia Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 79. Russia Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 80. Russia Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 81. Netherlands Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 82. Netherlands Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 83. Netherlands Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 84. Netherlands Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 85. Netherlands Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 86. Netherlands Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 87. Netherlands Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 88. Spain Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 89. Spain Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 90. Spain Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 91. Spain Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 92. Spain Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 93. Spain Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 94. Spain Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 95. Turkey Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 96. Turkey Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 97. Turkey Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 98. Turkey Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 99. Turkey Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 100. Turkey Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 101. Turkey Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 102. Poland Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 103. Poland Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 104. Poland Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 105. Poland Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 106. Poland Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 107. Poland Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 108. Poland Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 109. South America Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 110. South America Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 111. South America Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 112. South America Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 113. South America Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 114. South America Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 115. South America Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 116. South America Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
Figure 117. Brazil Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 118. Brazil Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 119. Brazil Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 120. Brazil Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 121. Brazil Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 122. Brazil Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 123. Brazil Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 124. Argentina Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 125. Argentina Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 126. Argentina Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 127. Argentina Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 128. Argentina Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 129. Argentina Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 130. Argentina Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 131. Asia-Pacific Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 132. Asia-Pacific Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 133. Asia-Pacific Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 134. Asia-Pacific Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 135. Asia-Pacific Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 136. Asia-Pacific Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 137. Asia- Pacific Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 138. Asia-Pacific Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
Figure 139. India Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 140. India Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 141. India Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 142. India Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 143. India Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 144. India Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 145. India Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 146. China Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 147. China Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 148. China Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 149. China Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 150. China Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 151. China Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 152. China Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 153. Japan Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 154. Japan Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 155. Japan Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 156. Japan Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 157. Japan Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 158. Japan Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 159. Japan Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 160. Australia Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 161. Australia Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 162. Australia Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 163. Australia Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 164. Australia Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 165. Australia Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 166. Australia Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 167. Vietnam Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 168. Vietnam Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 169. Vietnam Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 170. Vietnam Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 171. Vietnam Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 172. Vietnam Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 173. Vietnam Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 174. South Korea Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 175. South Korea Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 176. South Korea Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 177. South Korea Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 178. South Korea Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 179. South Korea Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 180. South Korea Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 181. Indonesia Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 182. Indonesia Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 183. Indonesia Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 184. Indonesia Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 185. Indonesia Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 186. Indonesia Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 187. Indonesia Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 188. Philippines Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 189. Philippines Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 190. Philippines Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 191. Philippines Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 192. Philippines Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 193. Philippines Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 194. Philippines Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 195. Middle East & Africa Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 196. Middle East & Africa Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 197. Middle East & Africa Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 198. Middle East & Africa Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 199. Middle East & Africa Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 200. Middle East & Africa Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 201. Middle East & Africa Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 202. Middle East & Africa Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
Figure 203. Saudi Arabia Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 204. Saudi Arabia Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 205. Saudi Arabia Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 206. Saudi Arabia Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 207. Saudi Arabia Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 208. Saudi Arabia Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 209. Saudi Arabia Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 210. UAE Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 211. UAE Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 212. UAE Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 213. UAE Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 214. UAE Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 215. UAE Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 216. UAE Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 217. South Africa Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
Figure 218. South Africa Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
Figure 219. South Africa Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
Figure 220. South Africa Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
Figure 221. South Africa Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 222. South Africa Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
Figure 223. South Africa Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 224. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 225. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 226. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 227. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022

Product Code: MX10661

Global lung cancer therapeutics market size was valued at USD 21.2 billion in 2022 and is expected to reach USD 56 billion in 2030, with a CAGR of 12.9% for the forecast period between 2023 and 2030F. Advancements in lung cancer therapeutics have risen due to heightened awareness of the disease in both developed and developing nations. The surge is attributed to the evolution of new medical diagnostic tools and state-of-the-art therapies and governments' amplified focus on healthcare infrastructure and improved treatment provisions. Another crucial catalyst propelling market growth is the increasing public awareness about diverse lung cancer treatment options.

Furthermore, factors such as growing disposable incomes, ongoing research and development for innovative technologies, the introduction of cutting-edge radiation therapy, the growing emphasis on personalized medicine, and the expanding economies in developing and underdeveloped regions are expected to bolster the market's growth trajectory throughout the projected period. Advancements in treatment options have significantly transformed the landscape of lung cancer therapeutics. The market has seen a surge in clinical trials and research exploring novel therapies, combination treatments, and early diagnosis methods, all aimed at improving patient outcomes and survival rates. As the global healthcare industry continues to prioritize oncology and personalized medicine, the lung cancer therapeutics market is expected to witness further advancements, driving improved survival rates, enhanced treatment efficacy, and better quality of life for patients diagnosed.

Rising prevalence of lung cancer

The global lung cancer therapeutics market has experienced a concerning upsurge in the prevalence of lung cancer cases. Lung cancer remains a significant health challenge, contributing to a substantial portion of cancer-related mortality worldwide. Factors such as widespread smoking, environmental pollutants, and lifestyle changes contribute to the escalating incidence of lung cancer. As projected by the American Cancer Society, in 2022, there were about 236,740 estimated new cancer cases and 130,180 estimated deaths in the United States.

Advancements in medical technology and increased awareness have led to earlier detection, improving survival rates. However, the rise in cases continues to propel the demand for more effective therapeutic interventions. Pharmaceutical companies, medical researchers, and healthcare providers are intensively focusing on developing innovative treatments, including targeted therapies, immunotherapies, and personalized medicine, to address this growing concern.

Advancement in Therapies

The global lung cancer therapeutics market has witnessed significant advancements in recent years, marked by innovative approaches and therapies. Immunotherapy, particularly immune checkpoint inhibitors such as Pembrolizumab and Nivolumab, have revolutionized lung cancer treatment by improving the body's immune response against cancer cells. Targeted therapies like EGFR inhibitors (such as Erlotinib and Osimertinib) and ALK inhibitors (such as Alectinib and Crizotinib) have shown remarkable efficacy in specific genetic mutations, leading to more personalized and effective treatment options. Moreover, advancements in precision medicine and the utilization of liquid biopsies for early detection of genetic mutations have improved diagnosis and treatment decision-making. Emerging technologies like CAR-T cell therapy and novel drug delivery systems offer promising avenues for the future. These developments reflect a paradigm shift towards more tailored, effective, and less invasive therapies, enhancing the prognosis and quality of life for lung cancer patients.

In July 2023, Iovance Biotherapeutics completed an initial evaluation of the Phase II trial for its autologous tumor-infiltrating lymphocyte (TIL) therapy, Lifileucel (LN-145), in patients diagnosed with metastatic non-small cell lung cancer (NSCLC). A review by the US FDA suggested that the trial design might be appropriate for accelerated approval. The encouraging feedback from regulators is grounded in the utilization of Lifileucel among patients with advanced, non-genomic mutant NSCLC who have undergone at least one FDA-approved targeted treatment.

Strategic Initiatives by Key Players

Key players in the global lung cancer therapeutics market have been actively involved in strategic initiatives to advance treatment options and improve patient outcomes. Many companies have focused on research and development, investing heavily in innovative therapies and technologies. Initiatives include the development of targeted therapies, immunotherapies, and precision medicine approaches tailored to specific genetic mutations and biomarkers.

Key pharmaceutical companies have introduced novel therapies targeting specific mutations and mechanisms involved in lung cancer progression. For example, the development and release of immunotherapies such as PD-1/PD-L1 inhibitors have marked a substantial breakthrough, offering improved treatment efficacy and reduced side effects compared to traditional chemotherapy. For instance, during June 2022, the European Commission granted approval to Novartis for Tabrecta in treating advanced non-small cell lung cancer with METex14 skipping.

Increasing Progress in Research and Development

The global lung cancer therapeutic market is experiencing significant growth, largely driven by the rising demand for precision medicine, a foundation of which is targeted therapies. The increase in demand can be attributed to the increasing research and development efforts in the field. For instance, in July 2023, the publication of a ten-year clinical trial revealed that lung cancer patients with the epidermal growth factor receptor (EGFR) mutation experienced notably increased survival rates when administered the drug Osimertinib. This development marks a significant stride in the realm of precision medicine and opens new opportunities for clinical laboratories to provide added value to both physicians and patients. The ADAURA project, led by scientists at Yale University and supported by AstraZeneca, a British pharmaceutical and biotechnology company, spearheaded this research. When pathology tests identify the EGFR mutation in a patient, there's substantial evidence indicating that the use of this targeted therapy could potentially decrease lung cancer-related fatalities by up to 50%.

Impact of COVID-19

Patients diagnosed with lung cancer faced an increased vulnerability to COVID-19 infection due to their common intake of immunosuppressive and chemotherapeutic medications during treatment. Managing these patients amid the pandemic posed a persistent challenge. To address this difficulty, multiple organizations collaborated to propose solutions and guidelines. For instance, as documented, in a January 2022 article in the Journal for Immunotherapy of Cancer, the European Society for Radiotherapy and Oncology and the American Society for Radiation Oncology joined forces to recommend treatments for various stages of lung cancer, including non-small cell lung cancer (NSCLC) in stages I-III, prophylactic cranial irradiation for small cell lung cancer (SCLC), and palliative radiation for NSCLC.

Furthermore, these recommendations catered to both an 'early pandemic scenario', where balancing patient and radiotherapy staff safety with lung cancer treatment was crucial, and a 'later pandemic scenario', which involved limited resources and necessitated patient prioritization. Consequently, the collective efforts of these organizations to confront treatment challenges amplified the demand for lung cancer therapeutics. Moreover, due to lockdown measures, better access to treatments is now available compared to the initial phase of the pandemic, resulting in the market reaching pre-pandemic growth levels and anticipated substantial growth in the forecast period.

Key Players Landscape and Outlook

Key industry leaders are heavily investing in research and development to expand their product portfolios, fostering further growth within the lung cancer therapeutics sector. These players are pursuing diverse strategic actions to broaden their global presence, such as introducing new products, entering contracts, engaging in mergers and acquisitions, amplifying investments, advancing market strategies, and establishing collaborations with other organizations. Competitors in the market must provide cost-effective solutions to expand and endure in a progressively competitive and burgeoning market landscape.

In April 2022, the United States FDA accepted the supplemental Biologics License Application for Enhertu (trastuzumab deruxtecan) for treating unresectable or metastatic non-small cell lung cancer (NSCLC) in adult patients, developed by AstraZeneca and Daiichi Sankyo.

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global Lung Cancer Therapeutics Market

4. Executive Summary

5. Global Lung Cancer Therapeutics Market Outlook, 2016-2030F

5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.1.2. By Volume
5.2. By Disease Type
- 5.2.1. Non-small Cell Lung Cancer (NSCLC)
- 5.2.2. Small Cell Lung Cancer (SCLC)
5.3. By Treatment
- 5.3.1. Chemotherapy
- 5.3.2. Radiation Therapy
- 5.3.3. Immunotherapy Targeted Therapy
- 5.3.4. Other
5.4. By Drug Class
- 5.4.1. Immunosuppressant
- 5.4.2. Monoclonal Antibodies
- 5.4.3. Tyrosine Kinase
- 5.4.4. Epidermal Growth Factors Receptors
- 5.4.5. Topoisomerase Inhibitors
- 5.4.6. Others
5.5. By Route of Administration
- 5.5.1. Oral
- 5.5.2. Injectable
5.6. By Distribution Channel
- 5.6.1. Hospital
- 5.6.2. Specialty Clinics
- 5.6.3. Clinical Research Institutes
- 5.6.4. Home Care Settings
- 5.6.5. Ambulatory Surgical Centres
5.7. By Region
- 5.7.1. North America
- 5.7.2. Europe
- 5.7.3. Asia-Pacific
- 5.7.4. South America
- 5.7.5. Middle East & Africa
5.8. By Company Market Share (%), 2022

6. Global Lung Cancer Therapeutics Market Outlook, By Region, 2016-2030F

6.1. North America*
- 6.1.1. Market Size & Forecast
  - 6.1.1.1. By Value
  - 6.1.1.2. By Volume
- 6.1.2. By Disease Type
  - 6.1.2.1. Non-small Cell Lung Cancer (NSCLC)
  - 6.1.2.2. Small Cell Lung Cancer (SCLC)
- 6.1.3. By Treatment
  - 6.1.3.1. Chemotherapy
  - 6.1.3.2. Radiation Therapy
  - 6.1.3.3. Immunotherapy Targeted Therapy
  - 6.1.3.4. Other
- 6.1.4. By Drug Class
  - 6.1.4.1. Immunosuppressant
  - 6.1.4.2. Monoclonal Antibodies
  - 6.1.4.3. Tyrosine Kinase
  - 6.1.4.4. Epidermal Growth Factors Receptors
  - 6.1.4.5. Topoisomerase Inhibitors
  - 6.1.4.6. Others
- 6.1.5. By Route of Administration
  - 6.1.5.1. Oral
  - 6.1.5.2. Injectable
- 6.1.6. By Distribution Channel
  - 6.1.6.1. Hospital
  - 6.1.6.2. Specialty Clinics
  - 6.1.6.3. Clinical Research Institutes
  - 6.1.6.4. Home Care Settings
  - 6.1.6.5. Ambulatory Surgical Centres
- 6.1.7. United States*
  - 6.1.7.1. Market Size & Forecast
  - 6.1.7.1.1. By Value
  - 6.1.7.1.2. By Volume
  - 6.1.7.2. By Disease Type
  - 6.1.7.2.1. Non-small Cell Lung Cancer (NSCLC)
  - 6.1.7.2.2. Small Cell Lung Cancer (SCLC)
  - 6.1.7.3. By Treatment
  - 6.1.7.3.1. Chemotherapy
  - 6.1.7.3.2. Radiation Therapy
  - 6.1.7.3.3. Immunotherapy Targeted Therapy
  - 6.1.7.3.4. Others
  - 6.1.7.4. By Drug Class
  - 6.1.7.4.1.1. Immunosuppressant
  - 6.1.7.4.1.2. Monoclonal Antibodies
  - 6.1.7.4.1.3. Tyrosine Kinase
  - 6.1.7.4.1.4. Epidermal Growth Factors Receptors
  - 6.1.7.4.1.5. Topoisomerase Inhibitors
  - 6.1.7.4.1.6. Other
  - 6.1.7.5. By Route of Administration
  - 6.1.7.5.1.1. Oral
  - 6.1.7.5.1.2. Injectable
  - 6.1.7.6. By Distribution Channel
  - 6.1.7.6.1.1. Hospital
  - 6.1.7.6.1.2. Specialty Clinics
  - 6.1.7.6.1.3. Clinical Research Institutes
  - 6.1.7.6.1.4. Home Care Settings
  - 6.1.7.6.1.5. Ambulatory Surgical Centres
- 6.1.8. Canada
- 6.1.9. Mexico

All segments will be provided for all regions and countries covered:

6.2. Europe
- 6.2.1. Germany
- 6.2.2. France
- 6.2.3. Italy
- 6.2.4. United Kingdom
- 6.2.5. Russia
- 6.2.6. Netherlands
- 6.2.7. Spain
- 6.2.8. Turkey
- 6.2.9. Poland
6.3. South America
- 6.3.1. Brazil
- 6.3.2. Argentina
6.4. Asia-Pacific
- 6.4.1. India
- 6.4.2. China
- 6.4.3. Japan
- 6.4.4. Australia
- 6.4.5. Vietnam
- 6.4.6. South Korea
- 6.4.7. Indonesia
- 6.4.8. Philippines
6.5. Middle East & Africa
- 6.5.1. Saudi Arabia
- 6.5.2. UAE
- 6.5.3. South Africa

7. Market Mapping, 2022

7.1. By Disease Type
7.2. By Treatment
7.3. By Drug Class
7.4. By Route of Administration
7.5. By Distribution Channel
7.6. By Region

8. Macro Environment and Industry Structure

8.1. Supply Demand Analysis
8.2. Import Export Analysis - Volume and Value
8.3. Supply/Value Chain Analysis
8.4. PESTEL Analysis
- 8.4.1. Political Factors
- 8.4.2. Economic System
- 8.4.3. Social Implications
- 8.4.4. Technological Advancements
- 8.4.5. Environmental Impacts
- 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.5. Porter's Five Forces Analysis
- 8.5.1. Supplier Power
- 8.5.2. Buyer Power
- 8.5.3. Substitution Threat
- 8.5.4. Threat from New Entrant
- 8.5.5. Competitive Rivalry

9. Market Dynamics

9.1. Growth Drivers
9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

10.1. Clinical Trials
10.2. Patent Landscape
10.3. Regulatory Approvals
10.4. Innovations/Emerging Technologies

11. Key Players Landscape

11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

14.1. Novartis AG
- 14.1.1. Company Details
- 14.1.2. Key Management Personnel
- 14.1.3. Products & Services
- 14.1.4. Financials (As reported)
- 14.1.5. Key Market Focus & Geographical Presence
- 14.1.6. Recent Developments
14.2. AstraZeneca
14.3. Boehringer Ingelheim
14.4. Bristol-Myers Squibb Company
14.5. Eli Lilly and Company
14.6. Hoffmann-La Roche
14.7. Merck & Co.
14.8. Pfizer Inc.
14.9. Teva Pharmaceutical Industries Ltd.
14.10. Abbvie (Allergan)
14.11. Johnson & Johnson (Janssen Pharmaceuticals)
14.12. Amgen Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

肺がん治療薬の世界市場：疾患の種類別・治療法別・薬剤クラス別・投与経路別・流通チャネル別・地域別の評価、機会と予測 (2016年～2030年)

Lung Cancer Therapeutics Market Assessment, By Disease Type, By Treatment, By Drugs Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2016-2030F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 新型コロナウイルス感染症 (COVID-19) が世界の肺がん治療薬市場に与える影響

第4章 エグゼクティブサマリー

第5章 世界の肺がん治療薬市場の将来展望 (2016年～2030年)

第6章 世界の肺がん治療薬市場の将来展望：地域別 (2016年～2030年)

第7章 市場マッピング (2022年)

第8章 マクロ環境と産業構造

第9章 市場力学

第10章 規制の枠組みとイノベーション

第11章 主要企業の情勢

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

第15章 戦略提言